Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Core Viewpoint - HUTCHMED (China) Limited announces the retirement of two Independent Non-executive Directors, Mr. Paul Rutherford Carter and Mr. Graeme Allan Jack, effective after the upcoming annual general meeting on May 13, 2025, leading to changes in the board's composition and committee leadership [1][2][3]. Board Changes - Mr. Paul Rutherford Carter and Mr. Graeme Allan Jack will not seek re-election and will retire from the Board at the AGM, ceasing their roles as chairmen and members of board committees [1][2]. - Professor Mok Shu Kam, Tony will be appointed as Senior and Lead Independent Non-executive Director, and Mr. Wong Tak Wai will become the chairman of the Audit Committee [2][6]. - Dr. Chaohong Hu will join the Audit Committee, and Dr. Renu Bhatia will chair the Remuneration Committee [6]. Contributions of Retiring Directors - Mr. Carter has significantly influenced the company's remuneration policies, aiding in employee retention and motivation [3]. - Mr. Jack has played a crucial role in overseeing financial reporting and audit processes, ensuring integrity and transparency [3]. Company Overview - HUTCHMED is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [4]. - The company has successfully marketed three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [4].